Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Observation for safety Clear all
Completed Phase 2 Interventional Results available

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

NCT05151744
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Vamikibart, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Arcadia, California • Torrance, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 25, 2026, 2:43 AM EDT
Active, not recruiting No phase listed Observational

LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1

NCT05975424
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Magnetic Resonance Imaging (MRI)
Diagnostic Test
Lead sponsor
Lineage Cell Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 25, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

NCT02600585
View directory record Official record
Conditions
Human Influenza
Interventions
Recombinant Influenza Vaccine, Inactivated Influenza Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
254,648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 25, 2026, 2:43 AM EDT
Not listed Phase 1 Interventional

Safety of Lymph Node Injection for Allergen Immunotherapy

NCT01982474
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Grass pollen extract, Placebo injection
Biological · Other
Lead sponsor
Amber Patterson
Other
Eligibility
15 Years to 24 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 25, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

NCT02804763
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Placebo, Dapirolizumab pegol (DZP)
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 25, 2026, 2:43 AM EDT
Completed Not applicable Interventional Results available

Telemedicine Control Tower for the Post-Anesthesia Care Unit

NCT04020887
View directory record Official record
Conditions
Elective Surgery
Interventions
Alertwatch - Interaction
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 25, 2026, 2:43 AM EDT
Completed No phase listed Observational Results available

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01613599
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 25, 2026, 2:43 AM EDT
Terminated Phase 2 Interventional

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

NCT05789537
View directory record Official record
Conditions
Hemophilia B with Inhibitor, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 25, 2026, 2:43 AM EDT
Completed No phase listed Observational Results available

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

NCT05260073
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Tirbanibulin
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 25, 2026, 2:43 AM EDT
Completed No phase listed Observational

Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

NCT03893890
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
Previously Treated with EN3835
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 25, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination

NCT01153906
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 25 Years · Female only
Enrollment
1,516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 25, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 25, 2026, 2:43 AM EDT
Not yet recruiting No phase listed Observational

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)

NCT07684313
View directory record Official record
Conditions
Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Tricuspid Valve Disease
Interventions
Edwards TRIFORMIS RESILIA heart valve
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 25, 2026, 2:43 AM EDT
Terminated No phase listed Observational Results available

Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route

NCT01531686
View directory record Official record
Conditions
Patients With Intraosseous Vascular Access Requiring Computed Tomography (CT) Exam
Interventions
Intraosseous delivery of CT contrast dye
Procedure
Lead sponsor
Vidacare Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Phoenix, Arizona • Sylmar, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 25, 2026, 2:43 AM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT07123038
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Interventions
Long Term Safety Monitoring Procedures
Other
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 71 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
10
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 25, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

NCT02936323
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
Interventions
PEN-221
Drug
Lead sponsor
Tarveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 25, 2026, 2:43 AM EDT
Completed No phase listed Observational

Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy

NCT05935956
View directory record Official record
Conditions
Neuralgia, Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions
Magnetic Peripheral Nerve Stimulation
Device
Lead sponsor
NeuraLace Medical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 25, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

NCT00329368
View directory record Official record
Conditions
Cancer
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Springfield, Illinois • Lansing, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 25, 2026, 2:43 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

NCT05857930
View directory record Official record
Conditions
Recurrent Wheezing, Wheezing Lower Respiratory Illness
Interventions
OM-85, Placebo
Drug
Lead sponsor
OM Pharma SA
Industry
Eligibility
6 Months to 72 Months
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 25, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

NCT02295501
View directory record Official record
Conditions
Acute Ebola Virus Disease
Interventions
INTERCEPT Plasma
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 25, 2026, 2:43 AM EDT
Terminated No phase listed Observational

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

NCT01652157
View directory record Official record
Conditions
Fibrosing Colonopathy
Interventions
ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy
Biological · Other
Lead sponsor
AbbVie
Industry
Eligibility
0 Months to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
123
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 25, 2026, 2:43 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

NCT03999801
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
AbbVie
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 25, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine

NCT04600388
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 25, 2026, 2:43 AM EDT
Completed No phase listed Observational

Safety Surveillance After Immunization With IXIARO

NCT01335412
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Sep 25, 2026, 2:43 AM EDT